Press release
Myocardial Infarction Pipeline Assessment, 2024 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | NuvOx Pharma, Ever Supreme Bio Technology, R-Pharm, Athera Biotechnologies,
"Myocardial Infarction Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myocardial Infarction Market.
The Myocardial Infarction Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Myocardial Infarction Pipeline Report: https://www.delveinsight.com/sample-request/myocardial-infarction-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Myocardial Infarction treatment therapies with a considerable amount of success over the years. Myocardial Infarction Key players such as - NuvOx Pharma, Ever Supreme Bio Technology, R-Pharm, Athera Biotechnologies, Celecor Therapeutics, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, and others, are developing therapies for the Myocardial Infarction treatment
• Myocardial Infarction Emerging therapies such as - NVX 308, UMSC01, RPH-104, ATH3G10, Zalunfiban, FDY-5301, Selatogrel, and others are expected to have a significant impact on the Myocardial Infarction market in the coming years.
• In April 2024, The EMPACT-MI phase III clinical trial indicated a 10% relative risk reduction in the primary composite endpoint of time to first hospitalization for heart failure or all-cause mortality for Jardiance® (empagliflozin) compared to placebo, although this did not achieve statistical significance. Jardiance was administered to adults within 14 days of an acute myocardial infarction, or heart attack, and showed a reassuring safety profile in this group. Additional pre-specified exploratory analyses revealed a 23% relative risk reduction for the time to first hospitalization due to heart failure and a 33% reduction in total hospitalizations for heart failure with Jardiance versus placebo.
Myocardial Infarction Overview
Myocardial infarction (MI), commonly known as a heart attack, occurs when blood flow to a part of the heart muscle is blocked for an extended period, causing damage or death to the heart tissue. This blockage is typically due to a buildup of fatty deposits, including cholesterol, which form plaques in the coronary arteries. When a plaque ruptures, it can create a clot that obstructs blood flow.
Get a Free Sample PDF Report to know more about Myocardial Infarction Pipeline Assessment-
https://www.delveinsight.com/report-store/myocardial-infarction-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Myocardial Infarction Pipeline Therapeutics Assessment
• Myocardial Infarction Assessment by Product Type
• Myocardial Infarction By Stage and Product Type
• Myocardial Infarction Assessment by Route of Administration
• Myocardial Infarction By Stage and Route of Administration
• Myocardial Infarction Assessment by Molecule Type
• Myocardial Infarction by Stage and Molecule Type
DelveInsight's Myocardial Infarction Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Myocardial Infarction product details are provided in the report. Download the Myocardial Infarction pipeline report to learn more about the emerging Myocardial Infarction therapies
Emerging Myocardial Infarction Drugs Under Different Phases of Clinical Development Include:
• NVX 308: NuvOx Pharma
• UMSC01: Ever Supreme Bio Technology
• RPH-104: R-Pharm
• ATH3G10: Athera Biotechnologies
• Zalunfiban: Celecor Therapeutics
• FDY-5301: Faraday Pharmaceuticals
• Selatogrel: Idorsia Pharmaceuticals
Myocardial Infarction Pipeline Analysis:
The Myocardial Infarction pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Myocardial Infarction treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myocardial Infarction Treatment.
• Myocardial Infarction key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Myocardial Infarction Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myocardial Infarction market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Myocardial Infarction drugs and therapies
https://www.delveinsight.com/sample-request/myocardial-infarction-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Myocardial Infarction Pipeline Market Drivers
• Increasing research and development activities
• Increasing number of public initiatives and awareness program on cardiovascular disease
Myocardial Infarction Pipeline Market Barriers
• The lack of emergency care awareness
• The heterogeneity of patients, along with the duration of treatment and modalities
Scope of Myocardial Infarction Pipeline Drug Insight
• Coverage: Global
• Key Myocardial Infarction Companies: NuvOx Pharma, Ever Supreme Bio Technology, R-Pharm, Athera Biotechnologies, Celecor Therapeutics, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, and others
• Key Myocardial Infarction Therapies: NVX 308, UMSC01, RPH-104, ATH3G10, Zalunfiban, FDY-5301, Selatogrel, and others
• Myocardial Infarction Therapeutic Assessment: Myocardial Infarction current marketed and Myocardial Infarction emerging therapies
• Myocardial Infarction Market Dynamics: Myocardial Infarction market drivers and Myocardial Infarction market barriers
Request for Sample PDF Report for Myocardial Infarction Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/myocardial-infarction-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1 Myocardial Infarction Report Introduction
2 Myocardial Infarction Executive Summary
3 Myocardial Infarction Overview
4 Myocardial Infarction- Analytical Perspective In-depth Commercial Assessment
5 Myocardial Infarction Pipeline Therapeutics
6 Myocardial Infarction Late Stage Products (Phase II/III)
7 Myocardial Infarction Mid Stage Products (Phase II)
8 Myocardial Infarction Early Stage Products (Phase I)
9 Myocardial Infarction Preclinical Stage Products
10 Myocardial Infarction Therapeutics Assessment
11 Myocardial Infarction Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Myocardial Infarction Key Companies
14 Myocardial Infarction Key Products
15 Myocardial Infarction Unmet Needs
16 Myocardial Infarction Market Drivers and Barriers
17 Myocardial Infarction Future Perspectives and Conclusion
18 Myocardial Infarction Analyst Views
19 Appendix
20 About DelveInsight
Related Reports:
Myocardial Infarction Market https://www.delveinsight.com/report-store/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Myocardial Infarction-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Myocardial Infarction Epidemiology https://www.delveinsight.com/report-store/myocardial-infarction-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Myocardial Infarction Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
Aneurysmal Subarachnoid Hemorrhage Market https://www.delveinsight.com/report-store/aneurysmal-subarachnoid-hemorrhage-sah-market
DelveInsight's "Aneurysmal Subarachnoid Hemorrhage (SAH) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Aneurysmal Subarachnoid Hemorrhage (SAH), historical and forecasted epidemiology as well as the Aneurysmal Subarachnoid Hemorrhage (SAH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Angelman Syndrome Market https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast
DelveInsight's "Angelman Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Angelman Syndrome, historical and forecasted epidemiology as well as the Angelman Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Autoimmune Pulmonary Alveolar Proteinosis Market https://www.delveinsight.com/report-store/autoimmune-pulmonary-alveolar-proteinosis-apap-market
DelveInsight's "Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of Autoimmune pulmonary alveolar proteinosis, historical and forecasted epidemiology as well as Autoimmune pulmonary alveolar proteinosis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Cardiovascular Calcification Market https://www.delveinsight.com/report-store/cardiovascular-calcification-market
DelveInsight's "Cardiovascular Calcification Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cardiovascular Calcification, historical and forecasted epidemiology as well as the Cardiovascular Calcification market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Charcot Marie Tooth Disease Market https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market
DelveInsight's 'Charcot-Marie-Tooth Disease Market Insights, Epidemiology, and Market Forecast 2032' report deliver an in-depth understanding of the Charcot-Marie-Tooth Disease, historical and forecasted epidemiology as well as the Charcot-Marie-Tooth Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
www.delveinsight.com
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myocardial Infarction Pipeline Assessment, 2024 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | NuvOx Pharma, Ever Supreme Bio Technology, R-Pharm, Athera Biotechnologies, here
News-ID: 3504569 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Myocardial
Driving Myocardial Infarction Market Growth in 2025: The Role of Increasing Numb …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Myocardial Infarction Market Size Growth Forecast: What to Expect by 2025?
Over the past few years, there has been a significant rise in the size of the myocardial infarction market. It is projected to expand from $2.05 billion in 2024 to $2.2 billion in 2025, exhibiting a compound annual…
Diabetes Epidemic Fuels Myocardial Ischemia Market Growth: An Emerging Driver Tr …
The Myocardial Ischemia Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Myocardial Ischemia Market?
The myocardial ischemia market has grown strongly. It will grow from $0.79 billion in 2024 to $0.85 billion in 2025 at a CAGR of 7.3%.…
Transforming the Myocardial Ischemia Market in 2025: Diabetes Epidemic Fuels Myo …
What Is the Expected Size and Growth Rate of the Myocardial Ischemia Market?
The market size for myocardial ischemia has demonstrated considerable growth over the last few years. There's a predicted growth from $0.79 billion in 2024 to $0.85 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. The substantial growth during the historical period can be credited to the use of telemedicine and remote monitoring, the discovery…
Myocardial Infarction Treatment Market Growth and Insights 2024
"The Business Research Company recently released a comprehensive report on the Global Myocardial Infarction Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
Myocardial Infarction Drugs Market
According to a new report published by Allied Market Research, titled, "Myocardial Infarction Drugs Market by Product Type (Analgesics, Antiplatelet Agents, Vasodilators, Thrombolytics, Anti-Thrombotic Agents, Glycoprotein IIb/IIIa Inhibitors, Î' Adrenergic Blockers, Angiotensin Receptor Blockers, and Angiotensin Converting Enzyme Inhibitors) and by Distribution Channel (Hospital Pharmacies, Hospitals, Drug Stores, and Online Drug Stores) - Global Opportunity Analysis and Industry Forecast, 2019-2026".
The Global market size of Myocardial Infarction Drugs Market was $XX…
Myocardial Ischemia - Pipeline Review, H1 2017 - Pharmaceutical Report
Lack of blood flow and oxygen to the heart muscle lead to cardiac ischemia, also called myocardial ischemia. The signs and symptoms may include chest pain, typically on the left side of the body (angina pectoris), neck or jaw pain, shoulder or arm pain, clammy skin, shortness of breath and nausea and vomiting. Myocardial ischemia can be caused by conditions such as coronary artery disease (atherosclerosis), blood clot, coronary spasm…
